downgrad ew
weak persist pressur look
structur transient impella appear transit
matur market outlook key catalyst
ecp btr stemi away move ew
assess market dynam pt
intermedi term thesi broken downgrad ew
growth momentum stori compani percutan mechan
circulatori support devic impella chang treatment paradigm high risk
percutan coronari intervent pci cardiogen shock patient
multibillion dollar limit competit strong reimburs led
sale compound-annual-growth-rate disconnect last quarter
growth slow abruptli previou overweight thesi abiom
rest recoveri level path sustain
growth intermedi term next gener devic impella ecp
impella btr data stemi pivot trial see move
new market ventricular assist devic st-elev myocardi
trend structur less confid acut recoveri
lower sale prior closer lower end
guidanc sale compound-annual-growth-rate declin lower
annual penetr y/i growth rate prior path re-
inflect growth less like near-term catalyst japan
potenti reimburs ex us geographi increment near-term
commerci invest may take hold remain encourag
materi growth driver ecp btr stemi see
driver away incorpor bull case downgrad
equal-weight lower pt prior base dcf valuat
discuss
stock share today updat dcf see
exhibit suggest share slightli fair valu said dont
clariti factor driven deceler cloud visibl multipl
expans posit revis lower convict
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
updat pt assum out-year penetr us pci us
shock europe/japan vs prior
termin margin termin growth assumpt remain unchang
pt impli ev sale multipl high growth smid-
cap comp group see exhibit lower peer growth balanc
better profit limit competit similar larg cap growth peer
intuit edward trade similar ebitda multipl
construct outlook name
reimburs next focu unlik get revis posit
prior year ipp final rate expect come day ipp
propos rate repres rate cut drg account
procedur prior year final rate revis meaning
posit think less like see revis year
expect final rate next year profit driver build
continuum care around impella linear relationship
reimburs util econom driver
adopt said level reimburs adequ even
cut still repres signific headroom impella procedur ergo
less convinc cut lead acut slowdown util near term
though may ad pressur sentiment investor question longer
term stabil rate correspond implic
weak persist sale miss consensu
weaker busi deceler unexpectedli
impella use high risk percutan coronari intervent pci fail
recov deceler pt impella use cardiogen shock deceler
pt manag lower guidanc y/i sale growth
y/i growth pressur sustain appear
structur idiosyncrat
wrong narr tie fda warn letter
impella rp right side heart failur percutan support lead acut
slow-down broader impella devic util see dilig
suggest structur shift given slow util trend prior rp
deeper invest commerci infrastructur util deceler
limit pci busi lap seri
catalyst pma expans better reimburs shock protocol
shift matur market outlook becom appar
confirm concern isol trend impair thesi
util issu link rp dilig support broad
weak relat rp util trend post fda warn letter
februari less impact acut slowdown week later
march month month volatil persist april saw robust
recoveri growth falter june pressur like multi
factori lack clariti caus solut driver
move equal-weight work assess dynam
shock pci growth variabl deceler pci slowdown
acut event march util deceler sinc
pt deceler pt deceler
pci recov anoth pt deceler shock
stabl unexpectedli deceler
pt suggest util trend isol pci support
commentari structur shift matur phase market
focu commerci infrastructur impact margin announc
commerci chang adjust territori increas rep hire
per quarter vs prior year call commerci
chang continu quarter add middl manag
made senior commerci personnel chang manag focus
increas breath depth could reflect smaller expect
market minimum suggest increment growth go get harder
expens lower annual margin expans
bp bp prior
could drive bullish bearish view
growth recoveri growth could respond near-term commerci
initi recov acut model said sens
issu manifest multipl quarter could take multipl quarter
resolv clear compani struggl cross chasm
next leg growth impact feel structur
lend v-bottom recoveri
 a/strateg option profit ebit margin
could synergist mani compani asset larg
less like market growth reimburs dynam linger valuat
question market sustain kept single-product
pipelin long term pipelin asset ecp btr well stemi
interest competit posit visibl key
product launch clinic data read-out away
abiom impella util trend market dynam keep us equal-weight
abiom impella util trend market dynam keep us equal-weight
growth slow seen prior
year teen y/i growth impella adopt
matur busi continu demonstr
oper leverag margin continu
expand bp annual
stemi pivot trial repres key
longer term expans opportun
market pivot begin
price target reflect multipl
base case sale high growth devic peer
support dcf valuat assum wacc termin
growth assum sale grow driven continu
impella penetr protect pci shock
impella penetr take faster expect util increas
exist impella site driven new product launch increas data
expans effort organ growth sustain
longer tail stemi repres meaning expans opportun
posit feasibl data multipl expand higher growth durabl longer
dcf analysi equat ev/sal
dcf analysi equat ev/sal
impella growth remain teen medium term repres pt
y/i penetr increas stemi repres meaning expans
opportun posit feasibl data rapidli scale busi reach ebit
margin multipl high growth peer lack
competit peer profit balanc transit
matur adopt curv
recent growth trend prove anomal impella sale growth deceler
doubl digit multipl contract reflect slower growth profil
potenti market size disappoint and/or expans delay
sustain reimburs broader
pma approv rp launch ecp
broader commerci launch japan
us stemi impli
impella rp roll-out japan roll-out
risk achiev price
risk pt includ expect
improv growth revenu growth
ii emerg competit ahead
expect market growth present
attract opportun new entrant
pressur share price iii
reimburs risk annual drg
reimburs cut
million except ep
sale
sale
sale
sale
compani data thomson reuter morgan stanley research valuat methodolog risk associ price target referenc research report pleas contact client support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan stanley research broadway attent research manag new york ny usa
chang net work capit
pv free flow
growth work capit
perpetu growth rate
equiti
after-tax cost debt
total discount valu
invest
st debt current portion lt debt
loss sale properti equip
net chang work capit
purchas invest
sale invest
net invest
chang equiti
effect exchang rate chang
net financ
begin year
end year
price target deriv discount cash flow model assum wacc
termin growth model project tavr market growth
billion drive ebit margin incorpor valu reflect
risk price target includ acceler competit
us near term robust commerci traction boston abbott/st jude
long term ii potenti pipelin develop failur mitral space
market opportun could larger aortic least sever year away iii
reimburs structur us europ could put downward pressur price
time
price target price target deriv discount cash
flow model assum wacc termin growth long-term
oper margin dcf impli price-to-earnings valuat cash ep
risk price target includ signific system placement deceler ii hernia
address market smaller anticip iii gynecolog urolog growth
materi slow turn neg iv intern procedur growth stall
competit
